An Eight-Week Study to Evaluate the Efficacy and Safety of SR58611A in Patients With Generalized Anxiety Disorder

Anxiety Disorders Clinical Trial

— ELECTRA  

Official title:

An 8-Week, Double-Blind, Placebo-Controlled, Multicenter Study With Paroxetine (20 mg q24) as Positive Control, Evaluating the Efficacy and Safety of 2 Fixed Doses of SR58611A (175 mg q12 and 350 mg q12) in Outpatients With GAD

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00332891
• Other study ID #: EFC5891
• Status: Completed
• Phase: Phase 3
• First received: June 1, 2006
• Last updated: March 6, 2009
• Start date: March 2006
• Est. completion date: April 2007

Study information

• Verified date: March 2009
• Source: Sanofi
• Contact: n/a
• Is FDA regulated: No
• Health authority: Serbia and Montenegro: Agency for Drugs and Medicinal DevicesPoland: Ministry of HealthCzech Republic: State Institute for Drug Control
• Study type: Interventional

Clinical Trial Summary

The purpose of the study is to evaluate the efficacy and safety of SR58611A in patients with Generalized Anxiety Disorder. The primary objective is to evaluate the efficacy of a 350 mg and 700 mg dose of SR58611A compared to placebo in patients with generalized anxiety disorder (GAD). The secondary objectives are to evaluate the efficacy of SR58611A on disability and quality of life in patients with GAD and to evaluate safety of SR58611A

Recruitment information / eligibility

• Status: Completed
• Enrollment: 508
• Est. completion date: April 2007
• Est. primary completion date: April 2007
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

• Patients suffering from generalized anxiety disorder (GAD) as defined by DSM-IV-TR criteria and confirmed by the Mini International Neuropsychiatric Interview (MINI) plus GAD Module

• Total score on the 14-item Hamilton Anxiety Rating Scale (HAM-A) equal or above 20.

Exclusion Criteria:

• Patients with a diagnosis of Major Depressive Disorder as defined by DSM-IV-TR within 6 months of study entry.

• Patients with a Montgomery-Asberg Depression Rating Scale (MADRS) total score of 18 or higher at screening or baseline visits.

• Patients having a moderate to high current risk for suicide.

• Patients with other current anxiety disorder assessed with the MINI: agoraphobia, social phobia, panic disorder, obsessive-compulsive disorder, post-traumatic stress disorder, acute stress disorder.

• Patients with a lifetime history according to the MINI of: bipolar disorders, psychotic disorders, antisocial personality disorder.

• Patients with severe or unstable concomitant medical conditions according to the Investigator's judgment.

• Females who are pregnant or lactating.

• Female patients of childbearing potential must use an effective method of birth control during the entire study period.

• Patients with positive test for any illicit drug included in the urine drug screen.

• Participation in a clinical trial of an experimental therapy within 3 months prior to screening

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Anxiety Disorders

Intervention

Drug:
• SR58611A

Locations

Country	Name	City	State
Bulgaria	Sanofi-Aventis Administrative Office	Sofia
Croatia	Sanofi-Aventis Administrative Office	Zagreb
Czech Republic	Sanofi-Aventis Administrative Office	Praha
Poland	Sanofi-Aventis Administrative Office	Warszawa
Serbia	Sanofi-Aventis Administrative Office	Belgrade

Sponsors (1)

Lead Sponsor	Collaborator
Sanofi

Countries where clinical trial is conducted

Bulgaria,  Croatia,  Czech Republic,  Poland,  Serbia, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The primary outcome of the study is the change from baseline to Day 56 of treatment in the Hamilton Anxiety Rating Scale (HAM-A) total score.
Secondary	The main secondary outcomes are the changes from baseline to Day 56 of treatment in the CGI Severity of Illness Score, percentage of patients with HAM-A treatment response and change from baseline in the HAM-A somatic and psychic anxiety factor scores.

External Links

•   Link